Abzena Plc

Abzena Group company PolyTherics is a biotechnology company that applies precision chemistry to develop protein and peptide-based drugs. PolyTherics is a biotechnology company that offers a comprehensive range of site-specific conjugation technologies and polymer-based technologies which are being applied to the development and enhancement of biologicals and other therapeutic entities.

Website:
www.abzena.com
Organisation type
Dr Donna Hackett
VP IP, Commercial & Legal Affairs 

Cello Health Consulting

Organisation type
Mr Adrian Walford
Head of Business Development 
Mr Steve Mather
Director of European Operations 
Mr Jim Hall
President 
Mr Jim McDermott
Consultant 

Clinical Network Services (UK) Ltd

Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA.

CNS creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.

CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical operations and biometrics team.

BioDesk’s expert consultants offer CMC/manufacturing, toxicology, clinical and regulatory affairs strategic advice and guide products efficiently through critical post-discovery development and into the clinic for the first time.

With over 15 years’ experience on more than 300 projects, CNS is one of the most experienced providers within the local market and a partner of choice for biotech companies.

CNS’s small-medium size is considered a big advantage when relating to similar sized clients, though CNS takes a global development/ regulatory approach to ensure value is strategically added at every stage of the product development life cycle.

Further information about CNS and its intelligent development services can be found at www.clinical.net.au

Organisation type
Mr Mark Reid
Director, BioDesk and Regulatory Affairs 
Ms Megan Hill
Business Development Manager 

Ex Scientia

Based on the ground breaking Nature publication ‘Automated design of ligands to polypharmacological profiles’ and with several commercial collaborations underway ex scientia is the first company to develop a systematic approach to tailoring drugs against polypharmacology profiles for superior clinical efficacy. We are exploiting our advanced technologies to develop compounds with tailored selectivity and in particular a portfolio of efficacious bispecific drugs.

Our bispecific design technology delivers efficacious small molecule drugs binding novel target combinations, either within or between gene families. By hitting multiple nodes in the cellular network simultaneously better clinical efficacy can be achieved.

Non-specific, promiscuous interactions with undesired proteins frequently cause drug toxicity and adverse effects. Our tailored selectivity technology can be applied to the discovery of drug candidates with desired selectivity, thereby reducing side effects and toxicity.

Advances in phenotypic screening are opening new ways to deliver improved medicines. Our phenotypic design technologies can generate and optimise effective molecules using high content phenotypic data without prior consideration of the targets. 

Organisation type
Dr Denise Barrault
Chief Commercial Officer 
Dr Mark Swindells
Chief Operating Officer